GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Exact Sciences Corporation (EXAS) [hlAlert]

Rating:
Sell EXAS
down 49.25 %

Exact Sciences Corporation (EXAS) rated Sell with price target $12 by Maxim Group

Posted on: Monday,  Oct 13, 2014  9:25 AM ET by Maxim Group

Maxim Group rated Sell Exact Sciences Corporation (NASDAQ: EXAS) on 10/13/2014. Previously Maxim Group rated Sell Exact Sciences Corporation (NASDAQ: EXAS) on
07/18/2012., when the stock price was $11.26. Since then, Exact Sciences Corporation has gained 97.07% as of 01/13/2016's recent price of $22.19.
If you would have followed the previous Maxim Group's recommendation on EXAS, you would have lost 49.25% of your investment in 1274 days.

EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/13/2014 9:25 AM Sell
None
24.85 12.00
as of 10/17/2014
1 Week up  3.37 %
1 Month down  -24.77 %
3 Months down  -45.47 %
1 YTD down  -102.29 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2014 9:25 AM Sell
None
14.48 8.00
4/18/2013 9:25 AM Sell
None
7.20 6.00
7/18/2012 10:28 AM Sell
None
11.26 7.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy